All In Biotech

Drug Trial Radar · NCT05699408

To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs

A Randomized, Open-Label, Controlled, Parallel-group, Multicenter Trial Comparing the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs

Last checked: Nov 19, 2026Latest source record: Feb 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 513 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

513

Actual

Start

Mar 31, 2023

Primary completion

Nov 23, 2024

Study completion Nov 23, 2024

Sponsor

Sponsor type
Industry
First posted
Jan 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy and safety of INS068 once daily (QD) in subjects with type 2 diabetes not adequately controlled with oral antidiabetic drugs compared to insulin Glargine QD for 26+26 weeks.

Conditions

  • Type 2 Diabetes

Interventions

  • INS068 injectionDrug

    INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial

  • Insulin GlargineDrug

    Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1cTime frame: Week 0 to Week 26

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.